Reviews
20 September 2020
Vol. 42 No. 3 (2020)
https://doi.org/10.4081/gimle.459

PHARMACOGENETIC TESTING IN ACUTE AND CHRONIC PAIN: A PRELIMINARY STUDY

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Pain, pharmacogenetics testing, pharmacotherapy, efficacy, side effects.
21
Views
12
Downloads

Authors

Lorenzo Panella
Dipartimento di Riabilitazione, ASST Gaetano Pini-CTO, Milano, Italy.
Laura Volontè
Dipartimento di Riabilitazione, ASST Gaetano Pini-CTO, Milano, Italy.
Nicola Poloni
Dipartimento di Medicina e Chirurgia, Divisione di Psichiatria, Università dell’Insubria, Varese, Italy.
Antonello Caserta
Dipartimento di Riabilitazione, ASST Gaetano Pini-CTO, Milano, Italy.
Marta Ielmini
Dipartimento di Medicina e Chirurgia, Divisione di Psichiatria, Università dell’Insubria, Varese, Italy.
Ivano Caselli
Dipartimento di Medicina e Chirurgia, Divisione di Psichiatria, Università dell’Insubria, Varese, Italy.
Giulia Lucca
Dipartimento di Medicina e Chirurgia, Divisione di Psichiatria, Università dell’Insubria, Varese, Italy.
Camilla Callegari
camilla.callegari@uninsubria.it
Dipartimento di Medicina e Chirurgia, Divisione di Psichiatria, Università dell’Insubria, Varese, Italy.

Background. Pain is one of the most common symptoms that weighs on life's quality and health expenditure. In a reality in which increasingly personalized therapies are needed, the early use of genetic tests that highlight the individual response to analgesic drugs could be a valuable help in clinical practice helping to reduce response times, to achieve a good level of analgesia and to reduce the risk of side effects and adverse events. The study aims to confront the clinical response to analgesic drugs with the result of pharmacogenetic testing in patients with persistent pain.
Methods. This preliminary study compares the genetic results of pharmacological effectiveness and tolerability analyzed with a Pharmacogenetic Test with the results obtained in clinical practice in 5 patients suffering from acute and chronic pain.
G Ital Med Lav Erg 2020; 42:3
Results. Regarding the genetic results of the 5 samples analyzed, 2 reports were found to be completely comparable to what found in clinical practice, while 3 reports showed that the profile of tolerability and effectiveness were partially discordant.
Conclusions. In light of the data, not completely overlapping with results observed in clinical practice, further studies would be appropriate in order to acquire more information on the use of the PGT in clinical practice.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1) Cordell WH, Keene KK, Giles BK, et al. The high prevalence of pain in emergency medical care. Am J Emerg Med 2002; 20(3): 165-9. 2) James S. Human pain and genetics: some basics. Br J Pain 2013; 7(4): 171-178. DOI: https://doi.org/10.1177/2049463713506408
3) Callegari C, Bortolaso P, Vender S. A single case report of recurrent surgery for chronic back pain and its implications concerning a diagnosis of Münchausen syndrome. Funct Neurol 2006; 21(2): 103-8. 4) Nielsen LM, Christrup LL, Sato H, et al. Genetic Influences of OPRM1, OPRD1 and COMT on Morphine Analgesia in a MultiModal, Multi-Tissue Human Experimental Pain Model. Basic Clin Pharmacol Toxicol 2017; 121(1): 6-12. DOI: https://doi.org/10.1111/bcpt.12757
5) Callegari C, Salvaggio F, Gerlini A, et al. Physical and psychic elements in chronic pain. Recenti Prog Med 2007; 98(4): 239-42. 6) Arellano AL, Martin-Subero M, Monerris M, et al. Multiple adverse drug reactions and genetic polymorphism testing. A case report with negative result. Medicine (Baltimore) 2017 Nov; 96(45): e8505. 7) Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30(2):191-7. DOI: https://doi.org/10.1016/0304-3959(87)91074-8
8) Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain(NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011; 63 Suppl 11: S240-52. DOI: https://doi.org/10.1002/acr.20543
9) lelmini M, Poloni N, Caselli I, et al. The role of pharmacogenetic testing in the treatment of bipolar disorder: preliminary results. Minerva Psichiatrica 2018; 59(1): 10-5. DOI: https://doi.org/10.23736/S0391-1772.17.01954-9
10) Morales-Espinoza EM, Kostov B, Salami DC, et al. Complexity, comorbidity, and health care costs associated with chronic widespread pain in primary care. Pain 2016 Apr; 157(4): 818-26. 11) lelmini M, Poloni N, Caselli I, et al. The utility of pharmacogenetics testing to support the treatment of bipolar disorder. Pharmgenomics Pers Med 2018 Mar 16; 11: 35-42. DOI: https://doi.org/10.1097/j.pain.0000000000000440
12) Bates MS, Edwards WT, Anderson KO. Ethnocultural influences on variation in chronic pain perception. Pain 1993; 52(1): 101-12. 13) Callegari C, lelmini M, Bianchi L, et al. Antiepileptic drug use in a nursing home setting: a retrospective study in older adults. Funct Neurol 2016; 31(2): 87-93. DOI: https://doi.org/10.1016/0304-3959(93)90120-E
14) Poloni N, Diurni M, Buzzi A, et al. Recovery style, symptoms and psychosocial functioning in psychotic patients: a preliminary study. Riv Psichiatr 2013; 48(5): 386-92.
15) Caselli I, Poloni N, lelmini M, et al. Epidemiology and evolution of the diagnostic classification of factitious disorders in DSM-5. Psychol Res Behav Manag 2017; 10: 387-394. DOI: https://doi.org/10.2147/PRBM.S153377
16) Sheng J, Liu S, Wang Y, et al. The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. Neural Plast 2017; 2017: 9724371. DOI: https://doi.org/10.1155/2017/9724371
17) Diurni M, Baranzini F, Costantini C, et al. Metabolic side effects of second generation antipsychotics in drug-naïve patients: a preliminary study. Riv Psichiatr 2009; 44(3): 176-8.
18) Bolla E, Bortolaso P, Ferrari M, et al. Are CYP1A2*1F and *1C associated with clozapine tolerability?: a preliminary investigation. Psychiatry Res 2011; 189(3): 483. DOI: https://doi.org/10.1016/j.psychres.2011.03.011
19) Ferrari M, Bolla E, Bortolaso P, et al. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Psychiatry Res 2012; 200(2-3): 1014-7. DOI: https://doi.org/10.1016/j.psychres.2012.07.002

How to Cite



PHARMACOGENETIC TESTING IN ACUTE AND CHRONIC PAIN: A PRELIMINARY STUDY. (2020). Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia, 42(3), 208-212. https://doi.org/10.4081/gimle.459
Copyright (c) 2020 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.